Garcia-Gisbert, Nieves http://orcid.org/0000-0002-8185-9786
Arenillas, Leonor
Roman-Bravo, David
Rodriguez-Sevilla, Juan Jose
Fernández-Rodríguez, Concepción
Garcia-Avila, Sara
Velez, Patricia
Gibert, Joan
Fernández-Ibarrondo, Lierni http://orcid.org/0000-0003-2612-0484
Salar, Antonio
Florensa, Lourdes
Bellosillo, Beatriz
Ferrer, Ana
Calvo, Xavier http://orcid.org/0000-0001-7934-9130
Funding for this research was provided by:
Roche
Janssen Pharmaceuticals
Gilead Sciences
Celgene
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI17/313, PI19/0005, PT20/00023, PI16/0153)
Generalitat de Catalunya (2017SGR205, 2017SGR437)
Thermo Fisher Scientific
Xarxa de Banc de Tumors de Catalunya Qiagen
Article History
Received: 7 July 2022
Revised: 7 October 2022
Accepted: 13 October 2022
First Online: 22 October 2022
Competing interests
: BB: Thermo Fisher Scientific (Research Funding, Consultancy, Speakers Bureau), Qiagen (Consultancy, Speakers Bureau), Roche (Research Funding, Speakers Bureau). AS: Roche (Research Funding, Speakers Bureau), Janssen Pharmaceuticals (Consultancy, Speakers Bureau), Gilead (Consultancy, Speakers Bureau), Celgene (Consultancy).